Radiopharmaceutica Product introduction - Nuclear Medicine InfoSite

...other pages and contents
Webmaster : Dr. Gianluigi Ciocia
Nuclear Medicine InfoSite
Title
Title
Go to content
Positron Emitting Radiopharmaceuticals
(some example and related targets)
Radiopharmaceutical
Target
18F-FDG
Glycolytic Cell
Metabolism
18F-FLT (Fluorthymidine)
Cell Proliferation
11C-Methionine
11C-Choline
18F-Choline
18F-MISO
Hypoxia
68Ga-DOTATOC
Receptor Distribution
18F-FES

For each particular molecule, there is a radiopharmaceutical. For each radiopharmaceutical, there is an objective of action. Synthetically, one of the main substrates of many cells is a basic molecule: glucose, subsequently transformed by chemical reactors and in the presence of 18F, in the main radiopharmaceutical: 18F-Fluorodeoxyglucose (18F-FDG).

RADIOPHARMACEUTICALS

Radiopharmaceuticals are the main tool of Nuclear Medicine. Without them, it would not be possible to give a clinical meaning to the emission of radioactivity given owned by the physical component (the isotope).  Various molecules (such as 18F-targeted, 11C-targeted and 68Ga-targeted, as example), after being approved in the experimental observation phase, have been used in advanced clinical approaches.
The use of radiopharmaceuticals (which are normed by law both in production and in quality control, a mandatory correlation), finds procedural guidelines and shared appropriativeness both in research and in clinical areas.
New fields and new molecules are steadily developed in University Centers with the support of specific industries, all around the world, in order to meet two key requirements at the same time:  

1. Ensuring a safe use in the diagnostics.  
2. Ensuring an improvement in the therapeutic perspective (metabolic radiotherapy or MRT) of the patient.

Back to content